Evolus (FRA:EVL) Debt-to-Revenue : 0.41 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Evolus Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Evolus's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €1.6 Mil. Evolus's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €122.5 Mil. Evolus's annualized Revenue for the quarter that ended in Dec. 2024 was €301.6 Mil. Evolus's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.41.

Evolus Debt-to-Revenue Historical Data

The historical data trend for Evolus's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus Debt-to-Revenue Chart

Evolus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Revenue

Get a 7-Day Free Trial

2.45

0.75

0.50

0.63

0.49

Evolus Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial															0.52	0.53	0.47	0.53	0.41

Competitive Comparison of Evolus's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evolus's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Evolus's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Evolus Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Evolus's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.641	+	122.489)	/	254.292
	=	0.49

Evolus's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.641	+	122.489)	/	301.576
	=	0.41

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

Evolus Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Evolus's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (FRA:EVL) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

EOLS:USA 0K16:UK

Address

520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660

Website

https://www.evolus.com

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Evolus Headlines

No Headlines